BidaskClub lowered shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a buy rating to a hold rating in a report released on Thursday morning.

Other equities research analysts have also issued reports about the stock. Mizuho restated a buy rating and issued a $20.00 price objective (down from $23.00) on shares of Ironwood Pharmaceuticals in a report on Friday, August 25th. Cowen set a $20.00 price objective on shares of Ironwood Pharmaceuticals and gave the stock a buy rating in a report on Monday, August 21st. Credit Suisse Group initiated coverage on shares of Ironwood Pharmaceuticals in a report on Monday, November 27th. They set a buy rating and a $19.00 price target for the company. Morgan Stanley reiterated a hold rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 4th. Finally, ValuEngine upgraded shares of Ironwood Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, November 29th. Nine research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Ironwood Pharmaceuticals currently has an average rating of Hold and a consensus target price of $17.88.

Ironwood Pharmaceuticals (NASDAQ IRWD) traded up $0.40 on Thursday, hitting $15.49. 535,000 shares of the stock traded hands, compared to its average volume of 1,305,285. The company has a debt-to-equity ratio of -22.31, a current ratio of 4.87 and a quick ratio of 4.86. Ironwood Pharmaceuticals has a 52-week low of $13.43 and a 52-week high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.07. The company had revenue of $86.80 million during the quarter, compared to analysts’ expectations of $73.59 million. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. Ironwood Pharmaceuticals’s revenue for the quarter was up 31.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.18) earnings per share. equities research analysts anticipate that Ironwood Pharmaceuticals will post -1.12 EPS for the current fiscal year.

In other news, CEO Peter M. Hecht sold 113,405 shares of the stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $15.12, for a total value of $1,714,683.60. Following the transaction, the chief executive officer now owns 4,696,917 shares in the company, valued at approximately $71,017,385.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 115,769 shares of company stock worth $1,752,491 in the last quarter. Company insiders own 7.63% of the company’s stock.

Several hedge funds have recently bought and sold shares of IRWD. Ameritas Investment Partners Inc. boosted its stake in Ironwood Pharmaceuticals by 5.8% during the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after buying an additional 648 shares during the period. Aperio Group LLC lifted its position in shares of Ironwood Pharmaceuticals by 11.9% during the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 1,410 shares during the last quarter. Amalgamated Bank lifted its position in shares of Ironwood Pharmaceuticals by 9.0% during the second quarter. Amalgamated Bank now owns 17,280 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 1,421 shares during the last quarter. Virtu KCG Holdings LLC lifted its position in shares of Ironwood Pharmaceuticals by 10.3% during the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 1,470 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Ironwood Pharmaceuticals by 5.0% during the second quarter. Legal & General Group Plc now owns 47,773 shares of the biotechnology company’s stock worth $900,000 after purchasing an additional 2,265 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “Ironwood Pharmaceuticals (IRWD) Stock Rating Lowered by BidaskClub” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/11/ironwood-pharmaceuticals-irwd-stock-rating-lowered-by-bidaskclub.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.